DOCSLIB.ORG

Interaction of Ischaemia and Encainide/Flecainide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interaction of Ischaemia and Encainide/Flecainide Br HeartJ_ 1995;74:631-635 631 Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I Br Heart J: first published as 10.1136/hrt.74.6.631 on 1 December 1995. Downloaded from Henry M Greenberg, Edward M Dwyer Jr., Judith S Hochman, Jonathan S Steinberg, Debra S Echt, Robert W Peters Abstract (Br Heart _J 1995;74:631-635) Objective-To determine whether an interaction between encainide or fle- cainide and intercurrent ischaemia could Keywords: antiarrhythmic drugs, ischaemia, CAST I, account for the observed increase in car- encainide/flecainide diac and sudden deaths in the study group in the Cardiac Arrhythmia Suppression Although ventricular tachycardia/ventricular Trial (CAST) I. fibrillation is a dominant mechanism of car- Design-CAST I was a randomised, dou- diac death in patients who have had a recent ble blind, placebo controlled study in myocardial infarction (< 1 year), and although which patients received the drug which the density of ventricular ectopy following suppressed at least 6 premature ventricu- shortly upon an acute infarction predicts sub- lar contractions per minute by 80% or sequent cardiac mortality, efforts to reduce episodes of non-sustained ventricular mortality by suppressing ventricular ectopy tachycardia by 90%. Arrhythmic sudden have failed.'-3 In the Cardiac Arrhythmia death or aborted sudden death were the Suppression Trial (CAST I)'2 the active drug study end points. Measured secondary groups had a higher cardiac and sudden death end points included recurrent myocardial mortality than the placebo group. infarction, new or increasing angina pec- In an earlier analysis mortality and morbidity toris, congestive heart failure, and syn- in CAST I Echt et al presented data suggesting cope. The CAST I database was analysed that the increase in mortality for the patients to determine which of three end points assigned to active drugs was associated with an occurred first-cardiac death or cardiac increase in angina pectoris and non-fatal rein- arrest, angina pectoris, or non-fatal farction in the placebo group.2 Because these recurrent infarction. They were regarded end points were not mutually exclusive, no as mutually exclusive end points. The conclusion could be drawn relating these two http://heart.bmj.com/ triad of cardiac or sudden arrhythmic observations, although Echt et al speculated death plus congestive heart failure and that an interaction might exist. Akiyama et al, syncope was similarly analysed. also in an analysis of CAST I data, showed Division of Cardiology, Results-It was assumed that recurrent that the 1 year mortality in patients with a St Luke's/Roosevelt non-fatal infarction and new or increas- non-Q wave myocardial infarction assigned to Hospital and Columbia ing angina pectoris were ischaemic in ori- the treatment group was markedly increased, University, New York, gin. The sum ofthese non-fatal ischaemic with a relative risk of nearly four times that of New York, USA on September 28, 2021 by guest. Protected copyright. H M Greenberg end points and sudden death were nearly the placebo group.4 Because of the enhanced J S Hochman identical in the placebo group (N = 129) ischaemic potential in the non-Q wave J S Steinberg and the treatment group (N = 131). The myocardial infarction, Akiyama et al postu- Division of Cardiology, one year event rate in each group was lated an ischaemia-drug interaction causing an University Hospital, and New Jersey 21%. However, the treatment group had a increased mortality in the treatment group. Medical School, much greater fatality rate (55 v 17; These two observations as well as the earlier Newark, New Jersey, P < 0.0001) than the placebo group. The suggestions made by the Task Force of the USA E M Dwyer same relation was found when the data Working Group on Arrhythmias of the were examined on the basis of drug expo- of led us to Division of Cardiology, European Society Cardiology,5 Vanderbilt University, sure rather than intention to treat. The evaluate the possibility that an interaction Memphis, Tennessee, temporal and circadian events were simi- between encainide/flecainide treatment and USA lar in each group and were consistent with ischaemia accounted for the excess mortality D S Echt an ischaemic pattern. No such patterns of the treatment group in CAST I. Division of Cardiology, Baltimore Department emerged from analysis of the presumed of Veterans Affairs non-ischaemic end points of congestive Hospital and heart failure and syncope. University of data that the and methods Maryland, Baltimore, Conclusions-These suggest Patients Maryland,USA interaction between active ischaemia and The CAST protocol has been described in R W Peters treatment with encainide or flecainide detail previously.'2 In brief, patients with at Correspondence to: may have been responsible for the least six premature ventricular depolarisations Dr H M Greenberg, Division of Cardiology, St Luke's increased mortality seen in the treatment per hour without ventricular tachycardia last- Roosevelt Hospital, 1000 group in CAST I. This conversion of a ing more than 15 beats at a rate of > 120 per 10th Avenue, New York NY 10019, USA. non-fatal to a fatal event emphasises the minute were eligible for enrolment after docu- Accepted for publication need for future antiarrhythmic drugs to mented myocardial infarction. Based on the 12 June 1995 be screened in ischaemic models. results of open label titration which demon- 632 Greenberg, Dwyer, Hochman, Steinberg, Echt, Peters strated a predefined, high-level suppression of the significance of differences between the ventricular ectopy (80% ofpremature ventricu- curves. lar contractions and 90% of runs of non-sus- tained ventricular tachycardia) patients were Br Heart J: first published as 10.1136/hrt.74.6.631 on 1 December 1995. Downloaded from randomly assigned to drug treatment or Results placebo. Holter electrocardiograms were We created two sets of data. One set used the obtained at 4 months and scheduled for 12 intention-to-treat data and the other the expo- months after the index myocardial infarction. sure-to-drug data censored three days after the The primary end point of the trial was start of individualised treatment. Figure lA-C arrhythmic death or cardiac arrest with resus- shows the intention to treat data. In each fig- citation, where these were presumed to be due ure the placebo and treatment groups are to ventricular arrhythmia. The site principal compared. When cardiac death and non-fatal, investigator classified each death and provided ischaemic end points of new/worsening angina a summary of the circumstances surrounding or non-fatal reinfarction were mutually exclu- the death. An events committee reviewed each sive end points, the estimated one year event death and differences were resolved by con- rate was 21% in both treatment and placebo sensus.6 There was an initial 86% concurrence groups (fig IA). Mortality was higher in between the events committee and the site the encainide/flecainide treatment group investigator. (P < 0-001) whereas non-fatal ischaemic end- In addition to the primary end point, all car- points were more frequent in the placebo diac deaths and secondary end points were group (P < 0 006) (figure 1B & C). The bar prospectively defined and tabulated.2 The sec- graph shows numerical data for the intention ondary end points included new or worsened to treat groups (fig 2). Increased mortality in angina pectoris; recurrent non-fatal myocar- the treatment group is balanced by the dial infarction; syncope, defined as unex- increased non-fatal ischaemic end points in pected, transient loss of consciousness not the placebo group. explained by physical trauma; and new or When patients were censored three days worsened congestive heart failure. Angina pec- after individualised treatment started, the toris was regarded as new if it was not present results were no different from the intention to at baseline and as worsened if the patient treat data. The censored data curves are deteriorated by at least one Canadian almost identical to the intention to treat curves Cardiovascular Society functional class. (not shown). One reason for the similarity of Congestive failure was regarded as new if the the two analyses may be that 34 of the 120 findings were not present at baseline and wors- patients in whom encainide/flecainide treat- ened if the patient's symptoms worsened by at ment (28%) was stopped were given another least one New York Heart Association func- primary antiarrhythmic drug. Nineteen of tional class. these 34 patients were given open label We analysed the CAST I database to deter- encainide or flecainide. http://heart.bmj.com/ mine which of three end points occurred first, We assumed that non-fatal syncope and either cardiac death or cardiac arrest, or congestive heart failure were non-ischaemic angina pectoris, or non-fatal recurrent infarc- clinical end points. The estimated survival to tion. These were regarded as mutually exclu- these end points combined with the mortality sive end points. For this study patients were end point showed a higher mortality for the censored when they reached the first end treatment group, reflecting that group's higher point. Death which followed quickly upon a mortality. However, unlike the presumed reinfarction or change in the angina pattern ischaemic end points (when the data were cen- on September 28, 2021 by guest. Protected copyright. was regarded as a fatal end point; by definition sored for cardiac death), there was no differ- a patient who did not survive an admission to ence between the placebo and drug groups. hospital for angina pectoris or recurrent There was no evidence of an interaction myocardial infarction was considered to have between drug assignment and these non- reached a fatal end point. We performed a ischaemic end points.
Load more

Recommended publications
  • Second Generation Antiarrhythmic Agents: Have We Reached Antiarrhythmic Nirvana?
    JACC Vol. 9. NO.2 459 February 1987:459-63 EDITORIAL REVIEWS Second Generation Antiarrhythmic Agents: Have We Reached Antiarrhythmic Nirvana? LEONARD N. HOROWITZ, MD, FACC, JOEL MORGANROTH, MD, FACC Philadelphia, Pennsylvania During the first half of the 20th century, antiarrhythmic some cases novel, but because their preapproval evaluations therapy was principally directed toward supraventricular ar­ followed a more rigorous and circumspect path. More in­ rhythmia; only relatively recently has therapy of ventricular formation is available to us so we can decide when and how arrhythmias been emphasized. In fact, significant pharma­ these agents should be employed. cologic treatment of ventricular arrhythmias was minimal Like all antiarrhythmic drugs of the first generation, the until routine use of quinidine and procainamide began in new agents have the potential to provoke or worsen ven­ the 1950s (1,2). The first generation oral antiarrhythmic tricular arrhythmias. These proarrhythmic effects vary in drugs, quinidine, procainamide and disopyramide, previ­ incidence and may present a major problem in certain patient ously constituted the principal antiarrhythmic agents for long­ groups such as those with sustained ventricular tachyar­ term treatment of ventricular arrhythmias in the United States. rhythrnias, reduced left ventricular function and conduction Compared with modem regulatory standards, the data on disturbances. In common with other antiarrhythmic drugs, which the use of these drugs was based were modest at best the second generation drugs have not been shown to prevent and rudimentary at worst. However, because good clinical sudden death in patients with ventricular ectopic activity. judgment compensates for a multitude of deficiencies, we These factors, along with efficacy and potential toxicity, have been able to provide effective antiarrhythmic therapy must be considered in selecting antiarrhythmic regimens for to many patients with this rather limited pharmacopoeia.
    [Show full text]
  • Formulation Development Strategies
    FORMULATION DEVELOPMENT STRATEGIES FOR ORAL EXTENDED RELEASE DOSAGE FORMS Dissertation zur Erlangung des akademischen Grades des Doktors der Naturwissenschaften (Dr. rer. nat.) eingereicht im Fachbereich Biologie, Chemie, Pharmazie der Freien Universität Berlin vorgelegt von ARAYA RAIWA aus Bangkok, Thailand May, 2011 1. Gutachter: Prof. Dr. Roland Bodmeier 2. Gutachter: Prof. Dr. Jürgen Siepmann Disputation am 9.Juni 2011 TO MY FAMILY ACKNOWLEDGEMENTS First and foremost, I wish to express my deepest gratitude to my supervisor, Prof. Dr. Roland Bodmeier for his professional guidance, helpful advices and encouragement. I am very grateful for his scientific and financial support and for providing me such an interesting topic. Furthermore, I am very thankful to him for the opportunity to support his editorial role in the European Journal of Pharmaceutical Sciences. I would like to thank Prof. Dr. Jürgen Siepmann for co-evaluating this thesis. Thanks are extended to Prof. Dr. Herbert Kolodziej, Prof. Dr. Johannes Peter Surmann and Dr. Martin Körber for serving as members of my thesis advisor committee. I am particular thankful to Dr. Andrei Dashevsky, Dr. Nantharat Pearnchob and Dr. Martin Körber for their very useful discussion; Dr. Burkhard Dickenhorst for evaluating parts of this thesis; Mrs. Angelika Schwarz for her assistance with administrative issues; Mr. Andreas Krause, Mrs. Eva Ewest and Mr. Stefan Walter for the prompt and diligent technical support. Sincere thanks are extended to Dr. Ildiko Terebesi, Dr. Burkhard Dickenhorst, Dr. Soravoot Rujivipat and Dr. Samar El-Samaligy for the friendly atmosphere in the lab My special thanks are owing to all members from the Kelchstrasse for their practical advice, enjoyable discussion and kindness throughout the years.
    [Show full text]
  • ACC/AHA/ESC Practice Guideline
    ACC/AHA/ESC Practice Guideline ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias*—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) Developed in Collaboration With NASPE-Heart Rhythm Society Committee Members Carina Blomström-Lundqvist, MD, PhD, FACC, FESC, Co-chair; Melvin M. Scheinman, MD, FACC, Co-chair; Etienne M. Aliot, MD, FACC, FESC; Joseph S. Alpert, MD, FACC, FAHA, FESC; Hugh Calkins, MD, FACC, FAHA; A. John Camm, MD, FACC, FAHA, FESC; W. Barton Campbell, MD, FACC, FAHA; David E. Haines, MD, FACC; Karl H. Kuck, MD, FACC, FESC; Bruce B. Lerman, MD, FACC; D. Douglas Miller, MD, CM, FACC; Charlie Willard Shaeffer, Jr, MD, FACC; William G. Stevenson, MD, FACC; Gordon F. Tomaselli, MD, FACC, FAHA Task Force Members Elliott M. Antman, MD, FACC, FAHA, Chair; Sidney C. Smith, Jr, MD, FACC, FAHA, FESC, Vice-Chair; Joseph S. Alpert, MD, FACC, FAHA, FESC; David P. Faxon, MD, FACC, FAHA; Valentin Fuster, MD, PhD, FACC, FAHA, FESC; Raymond J. Gibbons, MD, FACC, FAHA†‡; Gabriel Gregoratos, MD, FACC, FAHA; Loren F. Hiratzka, MD, FACC, FAHA; Sharon Ann Hunt, MD, FACC, FAHA; Alice K. Jacobs, MD, FACC, FAHA; Richard O. Russell, Jr, MD, FACC, FAHA† ESC Committee for Practice Guidelines Members Silvia G. Priori, MD, PhD, FESC, Chair; Jean-Jacques Blanc, MD, PhD, FESC; Andzrej Budaj, MD, FESC; Enrique Fernandez Burgos, MD; Martin Cowie, MD, PhD, FESC; Jaap Willem Deckers, MD, PhD, FESC; Maria Angeles Alonso Garcia, MD, FESC; Werner W.
    [Show full text]
  • Compounds and Bulk Powders
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 1014-13 Program Prior Authorization/Notification Medication Compounds and Bulk Powders P&T Approval Date 1/2012, 02/2013, 04/2013, 07/2013, 10/2013, 11/2013, 2/2014, 4/2014, 10/2014, 4/2015, 7/2015, 4/2016, 10/2016, 10/2017, 10/2018, 10/2019, 5/2020, 1/2021 Effective Date 4/1/2021; Oxford only: 4/1/2021 1. Background: Compounded medications can provide a unique route of delivery for certain patient- specific conditions and administration requirements. Compounded medications should be produced for a single individual and not produced on a large scale. A dollar threshold may be used to identify compounds which require Notification and must meet the criteria below in order to be covered. Drugs included in the compound must be a covered product. Claims for patients under the age of 6 will process automatically for First-Lansoprazole, First-Omeprazole, and Omeprazole + Syrspend SF compounding kits. 2. Coverage Criteriaa: A. Authorization for compounds and bulk powders will be approved based on all of the following criteria (includes bulk powders requested as a single ingredient such as bulk powder formulations of cholestyramine or nystatin when the powder formulation requested is not the commercially available FDA approved product): 1. The requested drug component is a covered medication -AND- 2. The requested drug component is to be administered for an FDA-approved indication -AND- 3. If a drug included in the compound requires prior authorization and/or step therapy, all drug specific clinical criteria must also be met -AND- 4.
    [Show full text]
  • Draft for Public Comment
    Draft for Public Comment Practice guideline update: Treatment of painful diabetic polyneuropathy Report of the Guideline Subcommittee of the American Academy of Neurology Authors (Alphabetical order—final order to be determined later in the guideline development process) Carmel Armon, MD, MSc, MHS1,Vera Bril, MD2, Brian C. Callaghan, MD, MS3, Lindsay Colbert, MA4, William S. David, MD, PhD5, Mary Dolan O’Brien, MLIS6, Kenneth Fink, MD, MPH7, Gary Franklin, MD, MPH8, Gary Gronseth, MD9, John Halperin, MD10, Lawrence B. Harkless, DPM11, Leslie Levine, PhD, VMD, JD12, Nicole Licking, DO13, Bruce A. Perkins, MD, MPH14, Michael Pignone, MD15, Raymond Price, MD16, Alexander Rae-Grant, MD17, Don Smith, MD18, Scott R. Wessels, MPS, ELS6 1. Department of Neurology, Tel Aviv University Sackler School of Medicine, Israel 2. Division of Neurology, Department of Medicine, Toronto General Hospital, ON, Canada 3. Department of Neurology, University of Michigan, Ann Arbor 4. The Foundation for Peripheral Neuropathy, Buffalo Grove, IL 5. Department of Neurology, Massachusetts General Hospital, Boston 6. American Academy of Neurology, Minneapolis, MN 7. Kamehameha Schools, Honolulu, HI 8. Department of Neurology, University of Washington, Seattle, WA 9. Department of Neurology, University of Kansas Medical Center, Kansas City 10. Department of Neurosciences, Overlook Medical Center, Summit, NJ 11. Western University Health Sciences College of Podiatric Medicine, Pomona, CA 1 Draft for Public Comment 12. Neuropathy Action Foundation, Santa Ana, CA 13. New West Physicians, Golden, CO 14. Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, ON 15. Department of Medicine, The University of Texas at Austin 16. Department of Neurology, University of Pennsylvania, Philadelphia 17.
    [Show full text]
  • Cordarone (Amiodarone Hydrochloride)
    Cordarone® (amiodarone HCl) TABLETS Rx only DESCRIPTION Cordarone (amiodarone HCl) is a member of a class of antiarrhythmic drugs with predominantly Class III (Vaughan Williams’ classification) effects, available for oral administration as pink, scored tablets containing 200 mg of amiodarone hydrochloride. The inactive ingredients present are colloidal silicon dioxide, lactose, magnesium stearate, povidone, starch, and FD&C Red 40. Cordarone is a benzofuran derivative: 2-butyl-3­ benzofuranyl 4-[2-(diethylamino)-ethoxy]-3,5-diiodophenyl ketone hydrochloride. The structural formula is as follows: Amiodarone HCl is a white to cream-colored crystalline powder. It is slightly soluble in water, soluble in alcohol, and freely soluble in chloroform. It contains 37.3% iodine by weight. CLINICAL PHARMACOLOGY Electrophysiology/Mechanisms of Action In animals, Cordarone is effective in the prevention or suppression of experimentally induced arrhythmias. The antiarrhythmic effect of Cordarone may be due to at least two major properties: 1. a prolongation of the myocardial cell-action potential duration and refractory period and 2. noncompetitive α- and β-adrenergic inhibition. Cordarone prolongs the duration of the action potential of all cardiac fibers while causing minimal reduction of dV/dt (maximal upstroke velocity of the action potential). The refractory period is prolonged in all cardiac tissues. Cordarone increases the cardiac refractory period without influencing resting membrane potential, except in automatic cells where the slope of the prepotential is reduced, generally reducing automaticity. These electrophysiologic effects are reflected in a decreased sinus rate of 15 to 20%, increased PR and QT intervals of about 10%, the development of U-waves, and changes in T-wave contour.
    [Show full text]
  • Treatment of Atrioventricular Node Reentrant Tachycardia with Encainide: Reversal of Drug Effect with Isoproterenol
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector 904 JACC Vol. 13, No. 4 March 15, 1989:904-10 Treatment of Atrioventricular Node Reentrant Tachycardia With Encainide: Reversal of Drug Effect With Isoproterenol IMRAN NIAZI, MD, GERALD NACCARELLI, MD* ANN DOUGHERTY, MD,* ROBERT RINKENBERGER, MD,* PATRICK TCHOU, MD, MASOOD AKHTAR, MD, FACC Milwaukee, Wisconsin and Houston, Texas To determine the efficacy of encainide in the treatment of paced cycle length with 1:l ventriculoatrial conduction was atrioventricular (AV) node reentrant tachycardia, Holter 337 f 56 ms in the control study, 551 t 124 ms with electrocardiographic (ECG) monitoring, exercise treadmill encainide infusion (p < 0.01 versus control) and 354 f 72 testing and programmed electrical stimulation were per- ms during isoproterenol infusion in the encainide-loaded formed in 16 patients while they were taking no medication state (p < 0.01 versus both control and encainide). and after steady state levels were reached during treatment During a mean follow-up period of 19 + 10 months, with encainide (75 to 200 mg/day; mean 117 + 47). In significant clinical recurrences occurred in 4 of the 10 addition, to study the possible reversal of drug effects by patients in whom tachycardia could still be initiated with sympathetic stimulation, AV node conduction and tachy- encainide (with or without isoproterenol). In contrast, no cardia induction were reassessed during isoproterenol infu- significant episodes occurred in the six patients in whom sion (1 to 3 pg/min), a dose calculated to increase the rest tachycardia could not be induced with encainide despite heart rate by 25 + 10%.
    [Show full text]
  • MEXITIL® (Mexiletine Hydrochloride, USP) Is an Orally Active Antiarrhythmic Agent Available As 150 Mg, 200 Mg and 250 Mg Capsules
    ® Mexitil (mexiletine hydrochloride, USP) Capsules of 150 mg, 200 mg and 250 mg Oral Antiarrhythmic Prescribing Information DESCRIPTION MEXITIL® (mexiletine hydrochloride, USP) is an orally active antiarrhythmic agent available as 150 mg, 200 mg and 250 mg capsules. 100 mg of mexiletine hydrochloride is equivalent to 83.31 mg of mexiletine base. It is a white to off-white crystalline powder with slightly bitter taste, freely soluble in water and in alcohol. MEXITIL has a pKa of 9.2. Chemically, MEXITIL is 1-methyl-2-(2, 6-xylyloxy) ethylamine hydrochloride and has the following structural formula: C11 H17 NO•HCl mexiletine hydrochloride, USP Mol. Wt. 215.73 (MEXITIL) MEXITIL capsules contain the following excipients: colloidal silicon dioxide, corn starch, magnesium stearate, titanium dioxide, gelatin, pharmaceutical glaze, simethicone, FD&C Red No. 40, and FD&C Blue No. 1; the MEXITIL 150 mg and 250 mg capsules also contain FD&C Yellow No. 10 and D&C Red No. 28. MEXITIL capsules may contain one or more of the following components: sodium lauryl sulfate, lecithin, shellac, and FD&C Blue No. 1 Aluminum Lake. CLINICAL PHARMACOLOGY Mechanism of Action MEXITIL (mexiletine hydrochloride, USP) is a local anesthetic, antiarrhythmic agent, structurally similar to lidocaine, but orally active. In animal studies, MEXITIL has been shown to be effective in the suppression of induced ventricular arrhythmias, including those induced by glycoside toxicity and coronary artery ligation. MEXITIL, like lidocaine, inhibits the inward sodium current, thus reducing the rate of rise of the action potential, Phase 0. MEXITIL decreased the effective refractory period (ERP) in Purkinje fibers.
    [Show full text]
  • Medications to Avoid in Long QT Syndrome
    Jackie Crawford Cardiac Inherited Disease Co-ordinator C/- Paediatric Cardiology; Level 3 Starship; Auckland City Hospital Private Bag 92024; Auckland Cardiac Inherited Disease Registry Phone: (09) 3074949 ext 23634 www.cidg.org Fax: (09) 6309877 Email: [email protected] Medications to be avoided, or requiring special caution, in people with Long QT syndrome This list includes medications which prolong the QT interval and is meant as a guide for people with Long QT syndrome, or acquired long QT interval from heart muscle disease, and their parents or guardians. It should not be seen as all inclusive. Those prescribing any medication to someone with Long QT syndrome should always check the drug specifications and contra-indications. The list has been compiled by review of publications and/or drug advice sheets provided with medications. Check also www.SADS.org and www.Torsades .org. Antibiotics Erythromycin, Clarithromycin, Gatifloxacin, levofloxacin, Moxifloxacin Sulfamethoxazole-trimethoprim (Septrin/Bactrim), Spiramycin, Pentamidine Antihistamines Terfenadine, Astemizole, Diphenhydramine, (These are particularly to be avoided (even in normal subjects) in combination with Erythromycin or grapefruit juice or the antifungals ketoconazole, miconazole, fluconazole or itraconazole) [Antihistamines that may be used safely are loratidine, cetirizine and fexofenadine, and phenergan] Appetite suppressants Fenfluramine, phentermine, Sibutramine Asthma treatments The Beta-2 agonists (e.g. Terbutaline, Salbutamol, Salmeterol) both work against
    [Show full text]
  • Get in Rhythm with the Safe and Effective Use of Antiarrythmic Drugs
    Get in Rhythm with the Safe and Effective Use of Antiarrythmic Drugs Karen J. McConnell, Pharm.D., FCCP, BCPS- AQ Cardiology, ASH-CHC Clinical Director and Cardiology Subject Matter Expert, Cardinal Health Clinical Associate Professor, University of Colorado Skaggs School of Pharmacy and Shannon W. Finks, Pharm.D., FCCP, BCPS- AQ Cardiology, ASH-CHC Professor of Clinical Pharmacy, University of Tennessee College of Pharmacy Clinical Specialist Cardiology, Veterans Affairs Medical Center Memphis Disclosure The program chair and presenters for this continuing education activity have reported no relevant financial relationships. Objectives . Design patient-specific treatment and monitoring plans for antiarrhythmic drugs (AADs) to treat atrial fibrillation (AF) . Differentiate among appropriate monitoring strategies for various agents used in ventricular arrhythmia suppression . Avoid potential adverse drug events with AADs by identifying important drug interactions . Ensure safe and effective dosing of AADs based upon specific patient factors Rhythm Rule #1 . Pharmacists play a vital role in the appropriate use of AAD dosing, adverse effects, interactions, and monitoring. Treatment and Monitoring of Atrial Fibrillation Atrial Fibrillation • Most common type of serious arrhythmia • In U.S., affects 2-5 million patients • Frequently seen with comorbidities • AF complicates management of comorbidity • Comorbidity complicates management of AF • Associated with stroke, heart failure, death • Most common arrhythmia requiring hospitalization Case #1: Mary Rhythm 60 y/o AA woman with a PMH including . Laboratory data: HFrEF (EF 35%), atrial fibrillation(AF), CKD, 140 110 18 HTN 105 . Inpatient Medications: 4.7 22 1.6 apixaban 5 mg twice daily lisinopril 20 mg daily BP 115/78 mm Hg HT 67 in metoprolol succinate 50 mg/day HR 70 bpm WT 75 kg furosemide 40 mg twice daily spironolactone 25 mg/day .
    [Show full text]
  • Possible Encainide-Induced Hypoproteinemia
    Possible Encainide-Induced Hypoproteinemia Lawrence L. Perry, MD, and Michael A. Oszko, PharmD Kansas City, Kansas ncainide is a class IC antiarrhythmic agent that is ular ejection fraction was determined to be 29%. An at­ Eused in the treatment of life-threatening ventricular tempt to lyse the right coronary artery occlusion using arrhythmias. Although a number of minor laboratory ab­ both intravenous and intracoronary streptokinase was un­ normalities have been reported with encainide therapy,1’2 successful. hypoproteinemia has not been among them. Reported In the coronary care unit, the patient was noted to have here is a case of hypoproteinemia and associated pedal frequent premature ventricular contractions and couplets, edema that developed in a patient during encainide ther­ He was placed on mexiletine; however, this treatment apy. The hypoproteinemia may be associated with encain­ failed to reduce the number of premature ventricular con­ ide therapy, since other causes of hypoproteinemia were tractions. The mexiletine was discontinued, and he was ruled out, and the patient’s edema resolved within 1 to 2 subsequently placed on encainide, 25 mg every 8 hours, weeks of the termination of the drug. which resulted in a dramatic reduction in the number of premature ventricular contractions. A 24-hour Holter ECG revealed only occasional premature ventricular con­ CASE REPORT tractions, no complex arrhythmias, and an episode of asymptomatic bradycardia (46 beats per minute). In addi­ tion, the patient was noted to have a low blood pressure, A 53-year-old man was admitted to the hospital on Octo­ though he remained asymptomatic. ber 15, 1987, with a chief complaint of “indigestion.” The patient was discharged on October 26, 1987, on Earlier in the day, he noted that his substemal discomfort encainide, 25 mg every 8 hours, aspirin 325 mg daily, and became more severe and was associated with diaphoresis, sublingual nitroglycerin as needed.
    [Show full text]
  • Egdb1de1.Pdf
    1 2 A todos los que me han dado la fuerza y la ilusión para llegar aquí A mis padres, hermanas y Ricard, por su cariño, sus cuidados y su ejemplo, sin vosotros no hubiese sido posible. A Iñaki, porque cuando te fuiste, te llevaste parte de mi vida, pero lo vivido me acompañará siempre, y tu recuerdo me ayuda a ser mejor. 3 4 EVALUATION OF CARDIOTOXICITY OF RUPATADINE, AN ANTIHISTAMINE, AS RECOMMENDED BY THE ICH E14 AIMS: To evaluate the effects of therapeutic and supratherapeutic doses of rupatadine on cardiac repolarization in line with a 'thorough QT/QTc study' protocol performed according to International Conference on Harmonization guidelines. METHODS: This was a randomized (gender-balanced), parallel-group study involving 160 healthy volunteers. Rupatadine, 10 and 100 mg od, and placebo were administered single- blind for 5 days, whilst moxifloxacin 400 mg/day was given on days 1 and 5 in open- label fashion. ECGs were recorded over a 23-h period by continuous Holter monitoring at baseline and on treatment days 1 and 5. Three 10-s ECG samples were downloaded at regular intervals and were analysed independently. The primary analysis of QTc was based on individually corrected QT (QTcI). Treatment effects on QTcI were assessed using the largest time-matched mean difference between the drug and placebo (baseline-subtracted) for the QTcI interval. A negative 'thorough QT/QTc study' is one where the main variable is around < or =5 ms, with a one-sided 95% confidence interval that excludes an effect >10 ms. RESULTS: The validity of the trial was confirmed by the fact that the moxifloxacin-positive control group produced the expected change in QTcI duration (around 5 ms).
    [Show full text]